The September 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The September issue of the Schedule includes several new/revised listings of note:

• Budesonide (Budenofalk) - new formulation
• Cabozantinib maleate (Cabometyx) - restriction change
• Migalastat hydrochloride (Galafold) - new medicine (transfer from LSDP)
• Trastuzumab deruxtecan (Enhertu) - new indication

Read PBS summary of changes